干扰素在恶性淋巴瘤自体移植后早期干预的应用

Application of interferon in early intervention after autologous transplantation of maligant lymphoma

目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10～50)个月,患者中位生存时间为37(31～45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。

Objective:To observe the clinical effect of early intervention with recombinant human interferon alpha-2 b(α-2 b IFN)after autologous hematopoietic stem cell transplantation(ASCT)in patients with non-Hodgkin’s lymphoma(NHL).Methods:18 cases of NHL were selected as the subjects,and disease assessment before transplantation were not CR.The patients in the trial group were given IFN 3 million U/alternate day after hematopoietic reconstitution till 3 months,and the control group did not receive interferon treatment.The overall efficacy and survival of the two groups were analyzed.Results:In the median follow-up period of 34(10~50)months,the expected median survival time was 37(31~45)months,and the 3-year progression-free survival(PFS)and overall survival(OS) were 54.7%、66.8%.After ASCT,there was no recurrence in the trial group within 1 year,and the recurrence rate was 12.5% in 2 years.In the control group,the recurrence rate was 20% in 1 years,and 30% in 2 years.Conclusion:Early IFN intervention after ASCT in patients with NHL is well tolerated and may reduce the early recurrence rate.